The Cancer Epidemiology and Chemoprevention Research Program engages a multidisciplinary group of laboratory investigators, population scientists, and clinicians who work collaboratively to elucidate the etiology of cancer and to develop Chemoprevention strategies. Emphasis is placed on mechanistic approaches as the basis for translating work from the bench to the bedside and to the community. The Program fosters discovery of novel chemopreventive agents by identifying their critical biologic targets and ultimately testing their efficacy on markers of early biologic response and on clinical disease. The Program further promotes investigations to identify carcinogenic factors and their biological effects at the molecular, genetic, and protein levels as well as inquiries into the environmental and biologic factors that modify these effects in populations. These efforts collectively involve observational studies, clinical trials (including proofof- principle and definitive Phase III trials), biomarker development, in vitro investigations, and animal studies including the use of genetically modified mice. Recent programmatic highlights include: (1) identifying induced cyclin proteolysis as a novel chemopreventive target;(2) successful conduct of proof-of-principle trials to validate this target in the clinic;(3) completion of large-scale, placebo-controlled randomized Chemoprevention trials, with findings of a reduced risk of colorectal adenoma following low-dose aspirin supplementation;and (4) extension of population-based molecular epidemiologic studies leading to detection of an association between human papillomavirus infection and squamous cell carcinoma of the skin in the general population. By promoting collaborations among basic and clinical scientists from 7 departments, the 19-member program has created advances that no single investigator could have made. Program members conduct research projects with current annual total cost funding of $10.9 million ($7.9 million from NCI, 72%). Program members published more than 300 papers during the renewal period, of which 32% derived from intra-programmatic and 33% from inter-programmatic collaborations. Over the next five years, we will continue to support initiatives with the greatest potential for clinical and public health impact on reducing the cancer burden, and to build on our growing areas of excellence in Chemoprevention, population-based studies of cancer incidence and progression, and the effects of early life exposures. The Program aims at continuing to strengthen its scientific accomplishments by organizing and fostering formal and informal mechanisms that promote collaboration and interactive projects between epidemiologists, laboratory scientists, and clinicians.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA023108-32
Application #
8014994
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2009-12-01
Budget End
2010-11-30
Support Year
32
Fiscal Year
2010
Total Cost
$73,936
Indirect Cost
Name
Dartmouth College
Department
Type
DUNS #
041027822
City
Hanover
State
NH
Country
United States
Zip Code
03755
Svedbom, Axel; Borgström, Fredrik; Hernlund, Emma et al. (2018) Quality of life after hip, vertebral, and distal forearm fragility fractures measured using the EQ-5D-3L, EQ-VAS, and time-trade-off: results from the ICUROS. Qual Life Res 27:707-716
Skolasky, Richard L; Scherer, Emily A; Wegener, Stephen T et al. (2018) Does reduction in sciatica symptoms precede improvement in disability and physical health among those treated surgically for intervertebral disc herniation? Analysis of temporal patterns in data from the Spine Patient Outcomes Research Trial. Spine J 18:1318-1324
Doubeni, Chyke A; Gabler, Nicole B; Wheeler, Cosette M et al. (2018) Timely follow-up of positive cancer screening results: A systematic review and recommendations from the PROSPR Consortium. CA Cancer J Clin 68:199-216
Sites, Brian D; Harrison, Jordon; Herrick, Michael D et al. (2018) Prescription Opioid Use and Satisfaction With Care Among Adults With Musculoskeletal Conditions. Ann Fam Med 16:6-13
Li, Bo; Wang, Yanru; Xu, Yinghui et al. (2018) Genetic variants in RORA and DNMT1 associated with cutaneous melanoma survival. Int J Cancer 142:2303-2312
Mittmann, Nicole; Stout, Natasha K; Tosteson, Anna N A et al. (2018) Cost-effectiveness of mammography from a publicly funded health care system perspective. CMAJ Open 6:E77-E86
Landon, Bruce E; Keating, Nancy L; Onnela, Jukka-Pekka et al. (2018) Patient-Sharing Networks of Physicians and Health Care Utilization and Spending Among Medicare Beneficiaries. JAMA Intern Med 178:66-73
Ghali, Fady; Celaya, Maria; Laviolette, Michael et al. (2018) Does Travel Time to a Radiation Facility Impact Patient Decision-Making Regarding Treatment for Prostate Cancer? A Study of the New Hampshire State Cancer Registry. J Rural Health 34 Suppl 1:s84-s90
Yang, Wei; Hosford, Sarah R; Traphagen, Nicole A et al. (2018) Autophagy promotes escape from phosphatidylinositol 3-kinase inhibition in estrogen receptor-positive breast cancer. FASEB J 32:1222-1235
Buckey, Jay C; Phillips, Scott D; Anderson, Allison P et al. (2018) Microgravity-induced ocular changes are related to body weight. Am J Physiol Regul Integr Comp Physiol 315:R496-R499

Showing the most recent 10 out of 1911 publications